Core One Labs Inc. (CLABF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 02:06PM EDT
| Previous Close | 0.1597 |
| Open | 0.1331 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.1331 - 0.1603 |
| 52 Week Range | 0.1159 - 0.5000 |
| Volume | |
| Avg. Volume | 4,113 |
| Market Cap | 7.549M |
| Beta (5Y Monthly) | 1.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
VANCOUVER, BC / ACCESSWIRE / December 8, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce the signing of an Initial Agreement (the "Agreement") with Cube Psytech Corp. ...
- ACCESSWIRE
Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods
VANCOUVER, BC / ACCESSWIRE / December 1, 2023 / Core One Labs Inc. ("Core One" or the "Company") (CNSX:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN: A3CSSU), an emerging leader in the field of neuroscience and psychedelics, is delighted to share the exciting ...
- ACCESSWIRE
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease
Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6, WKN:A3CSSU), (the "Company" or "Core One") is delighted to announce the receipt of additional positive results from its second round ("Round 2") of Stage 1 animal model studies.
© 2024 Yahoo. All rights reserved.